Hans Pharmaceutical: B7-H3 targeted antibody-drug conjugate HS-20093 combined with Atezolizumab has been granted breakthrough therapy designation by the National Medical Products Administration.

Hans Pharmaceutical announced that the group's self-developed B7-H3 targeted antibody-drug conjugate injection HS-20093, in combination with Atezolizumab monoclonal antibody, has been approved by the China National Medical Products Administration to be included in breakthrough therapeutic medications. It is intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed or recurred after platinum-based chemotherapy and is negative for driver genes.